Somatostatin Imaging of Neuroendocrine-Differentiated Prostate Cancer

被引：1

作者：

Hope, Thomas A. ^{[1
]}

Aggarwal, Rahul ^{[2
]}

Simko, Jeff P. ^{[3
,4
,5
]}

VanBrocklin, Henry F. ^{[1
]}

Ryan, Charles J. ^{[2
]}

机构：

[1] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA

[2] Univ Calif San Francisco, Div Hematol Oncol, Dept Med, San Francisco, CA 94143 USA

[3] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA

[4] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA

[5] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94143 USA

来源：

CLINICAL NUCLEAR MEDICINE | 2015年 / 40卷 / 06期

关键词：

prostate cancer; octreotide; neuroendocrine; somatostatin; FDG;

D O I：

暂无

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

After prolonged androgen deprivation therapy, a subset of castrate-resistant prostate cancer patients will develop neuroendocrine prostate cancer (NEPC) associated with resistance to further hormonal therapy and frequent visceral metastases. Imaging the presence of somatostatin receptors on the cancer cell surface may provide a readily available, noninvasive means to distinguish adenocarcinoma from NEPC. This distinction is important for therapeutic decision making and may open the door for developing novel radionuclide targets for the treatment of this aggressive subtype of prostate cancer. We describe a case of NEPC successfully imaged using In-111-labeled octreotide.

引用

页码：540 / 541

页数：2

共 50 条

[31] Neuroendocrine Cancer of the Prostate
Kranitz, Noemi
Szepesvary, Zsolt
Kocsis, Karoly
Kullmann, Tamas
PATHOLOGY & ONCOLOGY RESEARCH, 2020, 26 (03) : 1447 - 1450
[32] Neuroendocrine prostate cancer
Safina, S. Z.
Isyangulova, A. Z.
ONKOUROLOGIYA, 2023, 19 (02): : 94 - 100
[33] Neuroendocrine prostate cancer
Tritschler S.
Erdelkamp R.
Stief C.
Hentrich M.
Journal für Urologie und Urogynäkologie/Österreich, 2018, 25 (3): : 116 - 124
[34] CHARACTERIZATION OF A CELL-LINE (LCC-18) FROM A CULTURED HUMAN NEUROENDOCRINE-DIFFERENTIATED COLONIC-CARCINOMA
LUNDQVIST, M
MARK, J
FUNA, K
HELDIN, NE
MORSTYN, G
WEDELL, B
LAYTON, J
OBERG, K
EUROPEAN JOURNAL OF CANCER, 1991, 27 (12) : 1663 - 1668
[35] Somatostatin receptors imaging in gastroenteropancreatic neuroendocrine tumors.
Mura, A
Lebtahi, R
de Labriolle-Vaylet, C
Askienazy, S
GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 1998, 22 (10): : 809 - 818
[36] SOMATOSTATIN-RECEPTOR IMAGING OF NEUROENDOCRINE GASTROENTEROPANCREATIC TUMORS
SCHERUBL, H
BADER, M
FETT, U
HAMM, B
SCHMIDTGAYK, H
KOPPENHAGEN, K
DOP, FJ
RIECKEN, EO
WIEDENMANN, B
GASTROENTEROLOGY, 1993, 105 (06) : 1705 - 1709
[37] Theranostics in neuroendocrine tumours: somatostatin receptor imaging and therapy
Pencharz, Deborah
Gnanasegaran, Gopinath
Navalkissoor, Shaunak
BRITISH JOURNAL OF RADIOLOGY, 2018, 91 (1091):
[38] SOMATOSTATIN RECEPTOR IMAGING IN THE DIAGNOSIS AND TREATMENT OF NEUROENDOCRINE TUMORS
LAMBERTS, SWJ
REUBI, JC
KRENNING, EP
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1992, 43 (1-3): : 185 - 188
[39] The continuing evolution of somatostatin receptor imaging in neuroendocrine tumours
Navalkissoor, Shaunak
Buscombe, John R.
NUCLEAR MEDICINE COMMUNICATIONS, 2011, 32 (03) : 163 - 167
[40] Neuroendocrine Prostate Cancer: FOG-PET and Targeted Molecular Imaging
Spratt, D. E.
Zelefsky, M. J.
Fareedy, S.
Lindgren, S.
Osborne, J. R.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S209 - S209

← 1 2 3 4 5 →